Alerta

CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME

Resumen de: US2025276955A1

In one aspect, the present disclosure provides compounds which inhibit a coronavirus main protease. In another aspect, the present disclosure provides a method of treating, ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method prevents or treats COVID-19 in the subject.

Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A Antagonists

Resumen de: US2025277021A1

The present invention provides methods for preventing and treating cardiac dysfunction, including cardiomyopathy and heart failure. The methods of the invention feature the administration of an antagonist of Activin A, e.g., a therapeutically effective amount of an antibody that binds to and reduces or neutralizes the activity of human Activin A. The methods of the invention are useful in preventing and treating cardiac disease from multiple causes, including viral disease, e.g., COVID-19.

SARS-COV2 MAIN PROTEASE INHIBITORS

Resumen de: US2025276979A1

The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF

Resumen de: AU2025217394A1

This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV- 2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems. This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV- 2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems. ug h i s i n v e n t i o n r e l a t e s t o t h e u s e o f a n t i - v i r a l d r u g s w i t h d i f f e r e n t m e c h a n i s m s o f a c t i o n u g f o r t h e t r e a t i n g o r p r e v e n t i n g o f v i r a l i n f e c t i o n s s u c h a s - ( a l s o k n o w n a s - o - ) a n d r e d u c i n g m e d i c a l c o m p l i c a t i o n s r e l a t e d t o - v i r a l d i s e a s e h e p r e s

POLYSACCHARIDES FOR IV ADMINISTRATION THAT TREAT SARS-COV-2 INFECTIONS

Resumen de: US2025276005A1

The invention provides a method for treating SARS-COV-2 by administering an effective amount of pectin polysaccharides to a subject in need thereof.

EOM613 FOR TREATMENT OF COVID-19

Resumen de: US2025276030A1

Disclosed are methods of treating a subject with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection with EOM613. In several embodiments, a subject at risk of developing severe symptoms of SARS-COV-2 infection is selected for treatment. Also disclosed are methods wherein administering EOM613 reduces symptoms of SARS-COV-2 infection, including symptoms of cytokine storm syndrome or multisystem inflammatory syndrome.

CYTOLYTIC T CELL IMMUNOTHERAPY FOR HIGHLY PATHOGENIC CORONAVIRUSES

Resumen de: US2025276056A1

Compositions and methods to induce cytolytic T lymphocytes (CD8+) response, that is, MHC class I restricted T cell responses, to pathogenic and common cold coronaviruses, including a delivery platform for antigens consisting of a polyionic papillomavirus virus-like particle (VLP), with contiguous, negatively charged amino acids flanked by a cysteine residue inserted in the HI loop of the papillomavirus L1 protein. Antigens to be paired with the VLP include fusion peptide/proteins derived from a pathogenic coronavirus, and from the genetically most closely related human coronaviruses that commonly circulate in human populations, with N-terminal or C-terminal amino acids consisting of contiguous, positively charged amino acids preceded and/or followed by a cysteine residue and a C-terminal proteolytic processing sequence (AAYY) to enhance presentation of MHC class I epitopes.

PURIFICATION OF INFECTIVE VIRUS

Resumen de: WO2025181504A1

The invention relates to the field of ion exchange based purification processes and provides an improved method for the purification of lipid enveloped viruses. Use of the elution solution significantly enhances the efficiency of the recovery of the infective virus, in particular intact SARS-CoV-2 virions.

SARS-COV-2 N PROTEIN-SPECIFIC SINGLE-CHAIN ANTIBODY, AND FUSION PROTEIN AND USE THEREOF

Resumen de: US2025277788A1

A SARS-COV-2 N protein-specific single-chain antibody, a fusion protein, and use thereof are provided. The antibody includes a heavy chain variable region VH, a linker and a light chain variable region VL which are connected in sequence; the amino acid sequence of the heavy chain variable region VH is set forth in SEQ ID NO: 4; and the amino acid sequence of the light chain variable region VL is set forth in SEQ ID NO: 6. Compared with the conventional ELISA detection, the fusion protein can greatly shorten the detection time, can catalyze the substrate to generate a color reaction which can be recognized by naked eyes, and can perform detection without special instruments.

SINGLE DOMAIN ANTIBODY - SDAB/VHH AGAINST THE NUCLEOPROTEIN OF SARS-COV-2 VIRUS

Resumen de: WO2024089627A1

The invention provides a set of new single domain antibodies - sdAb/Vhh against the nucleoprotein (N) of SARS-CoV-2 and their use for diagnostic, therapeutic and prophylactic applications. Wherein the Vhh is selected from Vhh1 and/ or Vhh2 wherein the Vhh1 comprises 3 CDR having at least a 90% identity with aminoacidic sequence according to SEQ ID No 5, 6 and 7, and Vhh2 comprises 3 CDR having at least a 90% identity with aminoacidic sequence according to SEQ ID No 8, 9 and 10.

NUTRACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF POST COVID-19 CHRONIC FATIGUE / FATIGUE

Resumen de: WO2024089454A1

The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of post viral infection caused by the virus strain called SARS-CoV-2, or alternatively COVID- 19, chronic fatigue/fatigue.

Method for predicting COVID-19 infectiousness

Resumen de: GB2638668A

A method for predicting whether a subject infected with SARS-CoV-2 is likely to be infectious through airborne transmission or not is provided. The method includes determining expression of the TBLIXRI gene and optionally also the MIR4323 gene, the PPP3CB gene and the TRPM2 gene in a biological sample from a subject, typically from a subject who has tested positive for COVID-19. The method can include determining the expression levels of combinations of two or three of these genes, for example TBLIXRI and PPP3CB; TBLIXRI and MIR4323; TBLIXRI and TRPM2; TBLIXRI, PPP3CB and TRPM2; TBLIXRI, MIR4323 and PPP3CB; or TBLIXRI, MIR4323 and TRPM2. The level(s) of expression of the gene(s), through the quantification of mRNA level(s), can be compared to reference levels (non-infectious control subjects) to determine whether the subject is likely to be infectious. The biological sample is typically a blood sample. Also claimed are primer pairs for amplifying the genes.

Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation

Resumen de: US12403158B1

A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day, and parenteral including nasal sprays and inhalers. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.

CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-COV-2 INFECTION (PASC)

Resumen de: MX2025000142A

The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF

Resumen de: MX2025008873A

This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS~CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drags formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations that are incorporated into pulmonary and oral delivery systems.

POTENT NEUTRALIZING ANTIBODIES FOR PREVENTION AND TREATMENT OF COVID-19

Resumen de: US2025270296A1

Potent neutralizing antibodies for prevention and treatment of covid-19. Human chimeric antibodies (RBD-chAbs) specifically against SARS-COV-2 Spike(S) receptor-binding domain (RBD) are disclosed. Antibody cocktails or vaccine compositions comprising the RBD-chAbs are also disclosed. The RBD-chAbs, the antibody cocktails, and the vaccine compositions are effective for protection and/or treatment of COVID-19 and are potent against COVID-19 variants including United Kingdom variant B.1.1.7 (Alpha), South African variant B.1.351 (Beta), Brazil variant PI (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), Indian variants B.1.617.1 (Kappa) and B.1.617.2 (Delta).

CORONAVIRUS VACCINE

Resumen de: WO2025179238A2

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses against various SARS-CoV-2 variants of concern.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Resumen de: AU2024219190A1

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

ANTIVIRAL ANTIBODY AGAINST SARS-COV2 BINDING TO ACE2, AND USE THEREOF

Resumen de: US2025270297A1

The present invention relates to an antiviral antibody against SARS-CoV2 binding to ACE2 and a use thereof. The objective of the present invention is to prepare an antibody which binds to hACE2, and confirm that the antibody exhibits an antiviral effect against SARS-CoV2 by verifying that each antibody inhibits SARS-CoV2 virus entry into cells, thereby providing a composition comprising the antibody as a pharmaceutical composition for preventing or treating infection caused by SARS-CoV2.

NUTRACEUTICAL COMPOUNDS USEFUL IN THE TREATMENT OF CORONAVIRUS DISEASE

Resumen de: US2025268967A1

The present disclosure relates to use of and a method of administering a formulation that comprises a combination of at least two compounds selected from the group consisting of: levomenol, a ginseng extract, ascorbic acid; adenine derivatives (Adenosine; NAD+/NADH); ginkgolides such as ginkgolide A; and vitamin E; for treating one or more symptoms of a SARS-CoV-2 infection and for ameliorating symptoms that may persist following a SARS-CoV-2 infection.

COMPOSITIONS, KITS AND METHODS FOR DIRECT AMPLIFICATION FROM CRUDE BIOLOGICAL SAMPLES

Resumen de: US2025270619A1

Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the detection of target nucleic acids, including those from microbes and/or from infectious agents such as SARS-CoV-2 and other viruses. Embodiments described herein are designed to enable processing and analysis of the sample to detect target nucleic acids within the sample without requiring extraction and/or isolation of nucleic acid from the sample prior to subsequent processing steps. Samples analyzed can thus be “crude” biological samples that do not require pre-processing prior to placement in the workflow.

Camelid Antibodies for Use in Therapy and Diagnosis

Resumen de: US2025271431A1

The present invention relates to compositions and methods for use of the same for the diagnosis, prevention, treatment and prophylaxis of infections caused by coronavirus. In particular the present invention relates to Camelid heavy chain antibodies and antigen binding portions thereof that specifically bind to the Spike protein of a coronavirus, in particular SARS-CoV-2 virus and its variants.

ENGINEERED IMMUNE CELLS TO TARGET SARS-COV2

Resumen de: US2025268937A1

Provided herein are, inter alia, methods, compositions and kits for treating or preventing coronaviruses, e.g., SARS-CoV-2. Also included herein are kits for treating or preventing coronaviruses, e.g., SARS-CoV-2.

COMPOSITIONS AND METHODS FOR TREATING POST ACUTE SEQUELAE OF SARS-COV-2 INFECTION (LONG COVID)

Resumen de: US2025268948A1

Disclosed are methods and compositions for treating a subject with Long COVID (e.g., Post-Acute Sequelae of SARS CoV-2 (PASC)).

METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT

Nº publicación: US2025269005A1 28/08/2025

Solicitante:

TOPELIA AUST LTD ACN 652 771 670 [AU]
TOPELIA AUST LIMITED (ACN 652 771 670)

Resumen de: US2025269005A1

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herei